Loading transcript...
Click for full transcript
Chapters & Sections (84)
▼
00:00
Podcast Host Introduction and Megatrend Overview
00:31
Key Megatrends Highlighted by BlackRock Analyst
01:03
Impact of COVID-19 on Genomics and Immunology
01:34
Moderna CEO Introduction and Company Background
02:04
Moderna’s Mission and Early Years
02:35
Traditional Pharmaceutical Technologies vs. mRNA
03:06
Scientific Insight Behind mRNA Vaccines
04:08
Building Trust with Long‑Term Investors
05:10
Scalable Manufacturing and Digital Integration
06:53
Technical Challenges of mRNA Production
07:50
First Clinical Shipment and Variant Response
08:21
Challenges of Rapid Phase One Deployment
08:51
Accelerated Development vs. Traditional Timelines
09:24
Industrialization and Supply Chain Mobilization
09:55
Capital Injection for Manufacturing Scale‑Up
10:28
Operational Speed and Government Liaison
11:00
Technology Portfolio and Risk Mitigation
11:30
Contractual Funding Structure for Vaccine Development
12:33
Regulatory Guidance for Emergency Use Authorization
13:05
Data Requirements and Safety Database Scale
13:35
Strategic Portfolio Expansion Beyond COVID‑19
14:09
Diversification Across Therapeutic Areas
14:41
Maintaining Pipeline Momentum During a Pandemic
15:13
Leadership Team Structure for COVID-19
15:43
Executive Committee Focus on a Single Priority
16:14
mRNA as a Disruptive Digital Platform
16:46
Future of Flu Vaccines with mRNA
17:17
One-Shot Versus Multi-Shot Vaccine Strategies
17:49
Duration and Longevity of mRNA Vaccines
18:21
Predicting Vaccine Efficacy Over Time
18:53
One-Shot Boosts and Variant Adaptation
19:54
Pharmaceutical Attrition Rates and mRNA Impact
20:24
Molecular Safety and Side Effect Reduction
20:55
Exponential Growth of R&D Through mRNA
21:59
Future of Cancer Therapeutics and Immune Checkpoints
22:31
CEO Introduction and Company Mission
23:01
Clinical Trial Successes in Sickle Cell and Beta Thalassemia
23:31
CRISPR Mechanism Origin in Bacteria
24:02
Gene Editing for Disease Curing Paradigm
25:07
Founder’s Academic to Startup Journey
26:09
CRISPR in COVID-19 Diagnostics and Therapeutics
27:09
Rapid Vaccine Development Timeline
28:13
Emerging Platforms and Future Preparedness
30:47
Virtual Model for Physician Training in the Middle East
31:16
Regulatory Interaction Efficiency via Remote Meetings
31:19
Prioritizing Rare Diseases Based on Genetic Tractability
32:21
Case Study: GSD1A and CRISPR Intervention
32:53
Strategic Focus on Common Diseases like Cancer
33:24
Regenerative Medicine and Artificial Organs
34:27
Combining CRISPR with mRNA and Gene Therapy Platforms
35:30
Early Cancer Detection via Liquid Biopsy
36:02
CRISPR-Engineered Cell Therapies for Cancer
36:34
Big Data and AI in Gene Function Screening
37:06
Predictive Analytics for Gene Combination Effects
38:08
Long-Term Vision: Anti-Aging and Regenerative Medicine
39:10
Concept of Banking Stem Cells for Organ Replacement
39:41
Socioeconomic Inequality in Access to Cell Banking
40:15
Technical Aspects of Directing Stem Cells into Organs
40:48
Future Possibilities and Societal Implications of Extended Lifespan
41:18
Legal Disclaimer and Investment Advisory Notice
28m⏭ 1
26m⏭ 1
28m⏭ 1
37m⏭ 1
21m⏭ 1
23m⏭ 1
27m⏭ 1
27m⏭ 2
26m⏭ 1
28m⏭ 1
35m⏭ 1
27m⏭ 1
48m⏭ 1
1h 20m
1h 40m⏭ 3
31m⏭ 1
4h 6m⏭ 2
1h 22m
1h 16m⏭ 4
2h 15m⏭ 2
1h 50m⏭ 3
1h 0m⏭ 1
1h 28m⏭ 2
47m